Hims & Hers to Sell Wegovy, Ozempic
Telehealth platform Hims & Hers has partnered with Novo Nordisk to offer blockbuster weight-loss drugs Wegovy and Ozempic directly to consumers. The deal, which ends a prior dispute, integrates the popular GLP-1 therapies into Hims' digital platform, signaling a major shift toward direct-to-patient models for chronic disease management.
This new partnership follows a period of significant legal friction. Novo Nordisk had previously sued Hims & Hers for patent infringement over the telehealth company's sale of compounded semaglutide, the active ingredient in Ozempic and Wegovy. The dispute escalated when Hims briefly offered a $49 compounded oral version of semaglutide, which was quickly withdrawn after regulatory warnings and legal threats from Novo. The agreement marks a strategic pivot for Hims, moving from controversial compounded drugs to FDA-approved brand-name medications, thereby reducing significant legal and regulatory risks. As part of the deal, Hims will cease advertising compounded GLP-1 drugs. In return, Novo Nordisk is dropping its lawsuit, although it reserves the right to refile. For Novo Nordisk, the collaboration expands its direct-to-consumer reach, leveraging Hims' established digital platform and marketing engine to compete with Eli Lilly's Zepbound, which also utilizes telehealth partnerships. This move is part of a broader industry trend where pharmaceutical giants are increasingly bypassing traditional distribution channels to sell directly to patients. The market reacted swiftly to the news, with Hims & Hers' stock surging by over 40% following the announcement. While selling branded drugs is expected to increase revenue for Hims, analysts note it will likely come at the cost of lower profit margins compared to their compounded products. The telehealth weight loss market was estimated to be worth $6.9 billion in 2023. This deal is the second attempt at a partnership between the two companies; a similar agreement in April 2025 collapsed quickly after Novo accused Hims of illegally selling compounded versions of its drugs. The resolution of the semaglutide shortage by the FDA changed the regulatory landscape, removing the legal justification for many compounding pharmacies to produce copycat versions and increasing pressure on companies like Hims.
